Hikal Limited Q1 FY27 Results: Revenue ₹403 Cr, EBITDA ₹37 Cr, Pharma Growth 15.2%
Hikal Limited reported Q1 FY27 revenue of ₹403 Cr, up 6.2% YoY, with EBITDA at ₹37 Cr, up 47.4% YoY. The Pharmaceutical business grew 15.2% YoY to ₹233 Cr. The company is nearing completion of its US FDA remediation plan and received an EcoVadis Gold rating.
The results show a mixed performance with growth in pharmaceuticals but pressures in crop protection. The progress on US FDA remediation and the EcoVadis rating are positive long-term indicators, but the immediate financial impact is moderate.
The company reported revenue growth and improved EBITDA, with positive developments in its Pharmaceutical business and a significant achievement in receiving an EcoVadis Gold rating. While the Crop Protection business faced challenges, the overall outlook is cautiously optimistic.
Hikal Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a revenue of ₹403 crore and an EBITDA of ₹37 crore, with an EBITDA margin of 9.2%, a year-on-year growth of 47.4%.
The Pharmaceutical business demonstrated a revenue growth of 15.2% YoY to ₹233 crore. This growth was supported by portfolio expansion in differentiated APIs and specialty therapies, including Oncology, CNS, and Gastroenterology. The company is in the penultimate stage of its remediation plan with the US FDA and has invested significant resources to ensure compliance. Hikal also commissioned a new cGMP pilot plant in Pune to enhance pharmaceutical development and scale-up capabilities.
The Crop Protection business saw improved domestic demand in its Own Products segment, though CDMO demand remained subdued due to customer inventory adjustments and geopolitical developments leading to increased input costs. The company expects sequential improvement in this segment.
The Animal Health business continued its resilient performance, driven by stronger customer partnerships and new programs. The Personal Care business achieved a milestone with the commissioning of its dedicated Panoli manufacturing facility, focusing on expanding its UV filter skincare portfolio.
Hikal received a Gold rating from EcoVadis, placing it in the top 5% of companies globally. Looking ahead, the company expressed confidence in a stepwise recovery of revenues and profitability during the fiscal year.
What to do with a filing like this
Hikal Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hikal Limited. Read the original for the full detail.